Uses heart MRI scans to study heart tissue changes in people
Studies heart MRI scans in adults with possible heart muscle disease or inflammation.
Plain-language title generated from the registry record
Registry title: IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Key facts
- Where
- Frankfurt am Main, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have no clinical reason for a heart MRI scan and no known heart disease. It also studies people with a recent COVID-19 infection or vaccination.
- Age
- 18 years and over
- Sex
- Women and men can both join.
- Disease stage
- No known or clinically relevant heart disease, and no valid clinical reason for a heart MRI scan.
Main reasons for not taking part
- Cannot give informed consent
- Has an accepted reason not to have a contrast-enhanced heart MRI scan (MRI safety, contrast agent product information)
Read by machine on 12 November 2026.
Where in Germany
- University Hospital FrankfurtFrankfurt am Main, GermanyContact: Valentina O Puentmann, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Johann Wolfgang Goethe University Hospital
- Trial code
- NCT04444128
- Record updated
- 6 January 2026
- Original description
Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).Read full original descriptionShow less
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).
Inclusion: Able to provide informed consent; 18 years of age and over; Absence of a valid clinical indication for CMR, and/or known or clinically relevant cardiac disease.
Exclusion: accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent).